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Abstract: Tourette syndrome (TS) is a neuropsychiatric disorder with typical onset in 
childhood and characterized by chronic occurrence of motor and vocal tics. The disorder can 
lead to   serious impairments of both quality of life and psychosocial functioning, particularly 
for those individuals displaying complex tics. In such patients, drug treatment is recommended. 
The pathophysiology of TS is thought to involve a dysfunction of basal ganglia-related circuits 
and hyperactive dopaminergic innervations. Congruently, dopamine receptor antagonism of 
neuroleptics appears to be the most efficacious approach for pharmacological intervention. 
To assess the efficacy of the different neuroleptics available, a systematic, keyword-related search 
in PubMed (National Library of Medicine, Washington, DC) was undertaken. Much information 
on the use of antipsychotics in the treatment of TS is based on older data. Our objective was to 
give an update and therefore we focused on papers published in the last decade (between 2001 
and 2011). Accordingly, the present review aims to summarize the current and evidence-based 
knowledge on the risk-benefit ratio of both first and second generation neuroleptics in TS.
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Introduction
Tourette syndrome (TS) is a serious, often intractable neuropsychiatric disorder 
characterized by enduring though waxing and waning phonic (vocal) and motor tics. 
Contrary to the earlier perception of TS as a psychogenic disorder, its neurobiological 
basis has been proven, although the exact mechanisms are not yet fully understood.1 
Once tics have emerged, usually by the age of about 6–8 years, they reach a maximum 
at around 12 years. About 40% of all TS patients show a gradual to complete sponta-
neous remission of symptoms in early adulthood.2 Drug treatment is recommended 
for children who suffer from severe tics and adults with persistent and significantly 
impairing symptoms as a result of TS.
The pathophysiology is thought to involve a dysfunction of basal ganglia-related 
circuits and hyperactive dopaminergic innervations.3 Studies supporting the strong 
hypothesis of an imbalance in the dopaminergic system have shown an increased number 
of striatal4 and cortical5 dopamine receptors, as well as altered dopamine binding prop-
erties in the basal ganglia.6,7 Therefore, the main action of drugs used in the treatment 
of tics is the modulation of the dopaminergic metabolism. In this context, research 
is still focusing on the D2 receptor system5 and congruently D2 receptor antagonism 
appears to be the most efficacious approach for pharmacological intervention.8 For 40 
years, the beneficial effects of D2 receptor blocking in the treatment of tics have been 
reported, with an average success rate of 70%.9 In general, typical or first generation Neuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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antipsychotics are thought to have a very high dopamine 
blocking potency. Hence, they are thought to be very effective 
in ameliorating tics.10 However, these agents might be associ-
ated with severe adverse events, because a strong D2 receptor 
antagonism is connected with high rates of extrapyramidal 
symptoms (parkinsonism, akathisia, tardive dyskinesia) or 
even hyperprolactinemia. Furthermore, they also alter cho-
linergic, serotonergic, histaminergic, and alpha-adrenergic 
transmission and thereby might lead to weight gain, drowsi-
ness, and excessive sedation. Atypical or second generation 
neuroleptics usually have a greater affinity for 5-HT2 receptors 
than for D2 receptors which is associated with fewer extrapy-
ramidal side effects11 than seen under typical neuroleptics.
As a result of frequent adverse events caused by antipsy-
chotics, attempts have been made to use other medications 
for the treatment of TS such as noradrenergic agents (clo-
nidine, guanfacine, atomoxetine) or tetrabenazine, nicotine, 
tetrahydrocannabinol, talipexole, clonazepam, baclofen, 
levetiracetam, topiramate, lithium, or naloxone (as shown 
in the paper by Roessner et al9). As well as pharmacological 
treatment, psychotherapy or rather, habit reversal training12 
can be helpful if patients are willing to engage in it. Finally, 
deep brain stimulation should be considered for therapy-
resistant patients because it can successfully expand the limits 
of medication-based treatment options.13
Methods
Given the big impact of neuroleptics in the treatment of 
TS, the intention of this review is to give an update on the 
evidence-based, risk-benefit ratio of the different available 
antipsychotics.
Therefore, a systematic literature search was carried out in 
PubMed including articles published from 2001 to May 2011. 
The search terms were “antipsychotics and Tourette syndrome” 
plus “neuroleptics and Tourette syndrome”. By using a combi-
nation of these search terms we identified 175 articles published 
in German or English. In the first step, all titles and abstracts 
were screened carefully for aspects relevant to our main topic. 
Our second step was an analysis of the full texts to identify 
valuable information. In this process, we checked whether the 
information presented was collected in clinical studies with 
high methodological standards or from case reports or inciden-
tal findings. We used 43 articles in the present paper, found by 
using the research criteria described above; 132 articles were 
excluded. In addition, references for the identified articles were 
screened for further relevant literature not listed in PubMed 
or beyond our search period. In this way, another 89 articles 
were found and considered in the present review.
Results
Typical antipsychotics
Haloperidol
The butyrophenone haloperidol was the first drug used in 
treatment for TS and remains the most widely used agent for 
this indication worldwide. The first report on its empirical 
use in TS concerned an adult who had already undergone a 
frontal lobectomy.14 Haloperidol was approved by the Food 
and Drug Administration (FDA) for the treatment of adult TS 
patients in 1969 and for children in 1978.15 Due to its strong 
blocking effect on D2 receptors, tic reductions of 78%–91% 
at a maximum dosage of 10 mg have been estimated.16,17 The 
most commonly observed adverse events are extrapyramidal 
reactions (parkinsonism, tardive dyskinesia), neuroleptic 
malignant syndrome, drowsiness, restlessness, and sexual 
dysfunction. In our search period, we were unable to find any 
valuable studies. The approval of haloperidol is based mainly 
on its effectiveness known from older comparison studies 
with pimozide, fluphenazine, and placebo. An early random-
ized, double-blind and placebo-controlled study showed 
that haloperidol and pimozide decrease tic frequency 
  significantly.18 Some studies stated that   haloperidol is superior 
to both placebo and pimozide.16 However, in another study 
including 22 patients the effect of haloperidol was described 
as inferior to pimozide and even to placebo.19 Yet another 
study suggested that treatment with haloperidol is more often 
discontinued than with pimozide, even though both drugs 
produced comparable relief of symptoms.20 Additionally, 
haloperidol produced significantly more acute dyskinesia/
dystonia than pimozide. Some studies suggested that other, 
similar, agents such as pimozide19 and fluphenazine21 may 
be as efficacious as haloperidol, but with fewer side effects 
and a slightly better patient tolerance.
Conclusion: Although the evidence is not consistent, based 
on clinical experience, haloperidol may be an effective 
agent for the treatment of TS. Older studies (data collec-
tion before 1997) suggested that it is less tolerable and 
is more often associated with adverse events than other 
typical neuroleptics. For this reason, haloperidol should 
be used mainly as a spare medication in severely diseased 
patients.22
Pimozide
Pimozide is a D2 receptor antagonist which in addition 
blocks calcium channels11 and to a lesser extent D1 receptors. 
It exhibits less noradrenaline (alpha1) antagonism than 
haloperidol, and less sedation.22 Pimozide can be associated 
with severe arrhythmia and prolongation of the QTc Neuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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  interval.23 The most recent article about the efficacy of 
pimozide is a comprehensive Cochrane review from 2009 
reporting on six randomized controlled trials with a total 
of 162 participants.24 The comparison between pimozide, 
haloperidol, and risperidone revealed inconsistent results. 
Pimozide, however, was shown to be considerably more 
effective than placebo. Inconsistency of results is brought 
about by three double-blind, placebo-controlled trials of 
pimozide versus haloperidol: one revealed equal efficacy, 
another found haloperidol slightly more effective than 
pimozide, while yet another showed pimozide to be superior 
to haloperidol. Pimozide is further described as having 
fewer side effects (including sedation and extrapyramidal 
symptoms) than haloperidol. In two trials comparing 
pimozide with risperidone, no significant differences between 
the two drugs in terms of efficacy or side-effect profile could 
be identified.25,26
Conclusion: In our opinion, pimozide is indicated for the 
suppression of tics in patients who have failed to respond 
  satisfactorily to standard treatment with the frequently recom-
mended agent risperidone. As a rather older   compound with 
a considerable cardiac risk profile, we   support the appraisal 
for pimozide as a reserve   treatment especially because no 
substantial new data have been acquired in recent years. 
Singer favored pimozide as second choice medication in his 
helpful suggestions.11
Fluphenazine
Fluphenazine acts as both a D1 and D2 receptor antagonist.11 
It has been used particularly in the US for many years to 
treat TS, though it has simply been studied systematically.9 
Our search period included only a small amount of current 
data. A naturalistic follow-up study from 2004 including 
41 patients indicated that treatment with fluphenazine for 
at least one year was safe and effective.27 A retrospective 
review from 2009 also showed fluphenazine to be an effective 
and well-tolerated therapy.28 The main data were collected 
in a few older studies including placebo-controlled, double-
blind trials between 1982 and 1985 which revealed that 
fluphenazine is effective in controlling tics, while having 
fewer side effects than haloperidol (small, open-label 
studies).29–31
Conclusion: Although fluphenazine has been shown to be 
an effective and well-tolerated therapy for TS, we would not 
unconditionally recommend its use due to the lack of recent 
studies comparing this drug to newer medications such as 
atypical antipsychotics. Yet, it is also favored by Singer as 
second choice medication.11
Atypical antipsychotics
Benzamide
The benzamides (tiapride, sulpiride, and amisulpride) are 
a class of amides of benzoic acid and further selective D2 
receptor antagonists.32 Substituted benzamides are effective 
in the treatment of tics and it seems that the occurrence of 
extrapyramidal side effects is unusual.22
In Germany, benzamides (especially tiapride) are 
used as first-line medication in the treatment of TS, 
particularly in children and young adults. The lack of 
studies investigating the efficacy of these agents might 
be explained by the fact that tiapride and sulpiride are not 
available in the US.8
Tiapride
Tiapride has a selective antagonistic effect on D2 receptors, 
especially in the ventral striatum and in parts of the limbic 
system.9 Although this drug is in general well-suited for the 
treatment of hyperkinetic movement disorders which are 
associated with functional dopamine hyperactivity33 and 
is even considered as first choice in European guidelines,9 
no clinical studies focusing on the treatment with tiapride 
in humans were found in our search period. There is only 
one case report from 2004 about a patient with severe side 
effects such as massive weight gain, hyperprolactinemia, 
amenorrhea, and sedation under therapy with tiapride.34 
Nevertheless, there are two animal studies investigating the 
effects of tiapride, suggesting that this drug does not lead to 
long-lasting alterations of dopamine concentration or other 
severe short- and long-term adverse reactions in young 
rats.35,36 Thus evidence for its clinical efficacy in humans 
is mostly based on older studies. Since the 1970s, some 
case reports and placebo-controlled studies have reported 
the success of TS treatment with tiapride.37–39 Only one 
randomized, double-blind, and placebo-controlled crossover 
study from 1988 investigated the effects of tiapride in 17 
children. The results yielded beneficial therapeutic effects on 
tic symptomatology, while no adverse effects on children’s 
cognitive functioning were reported.40 Drowsiness, modest 
transient hyperprolactinemia, and moderate weight gain have 
been observed as side effects.
Conclusion: Despite the lack of actual studies, the   treatment 
of TS with tiapride should still be considered,   especially 
because of its moderate side effects, which have been 
confirmed by translational studies and clinical   experience.9 
Nevertheless, further well-designed studies and head-to-
head comparisons would be desirable.Neuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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Sulpiride
Sulpiride is a highly selective D2 and D3 receptor antagonist 
with antipsychotic and antidepressant mechanisms as well 
as anxiolytic effects.41 It was first used for the treatment 
of TS in 1970.42 Usually, few adverse events are reported 
with its use (eg, sedation and sustained drowsiness in up to 
25%).32 Less frequent side effects are restlessness, as well 
as sleep problems43 and depressive symptoms, which occur 
despite the antidepressant and mood-stabilizing effects of 
sulpiride.44 Increased appetite and as a consequence weight 
gain may occur, which is probably attributable to the stimu-
lating effects of prolactin secretion causing galactorrhea and 
amenorrhea.45,46 Due to its rare extrapyramidal and vegetative 
side effects, sulpiride is probably one of the most prescribed 
medications in the treatment of tics in TS in Europe.18
One recent prospective, open-label, study investigated 
the effect of low-dose sulpiride treatment of children and 
adolescents with TS or chronic tic disorder. The 189 treated 
patients demonstrated a significant reduction in tic symp-
tomatology after a period of 6 weeks. The most common 
adverse events were sedation (16% of the patients), which 
often disappeared 1–2 weeks after treatment onset.47 These 
promising results are supported by older studies. Robertson 
and colleagues for example documented in 1990 a posi-
tive effect of treatment with sulpiride in 59% of patients. 
  Furthermore, besides tic reduction, a significant decrease 
in other phenomena such as echophenomena, aggression, 
subjective tension, and   obsessive compulsive traits was 
found.44 In a placebo-  controlled crossover study the treat-
ment effects of fluvoxamine and sulpiride in patients suf-
fering from TS and obsessive compulsive   disorders were 
compared. Sulpiride monotherapy was shown to reduce tics 
significantly.48
Conclusion: Given the previously described data, the treat-
ment of mild-to-moderate TS or chronic tic disorder with 
sulpiride can be recommended.9,44 Even in low doses, 
sulpiride seems to be effective and is usually associated with 
few adverse events.
Amisulpride
Amisulpride is a highly selective benzamide with 10× higher 
affinity to D2 and D3 receptors than sulpiride and with 
little activity at serotonergic, histaminergic, or muscarinic 
  receptors.32 While the agonistic effects on presynaptic 
D2/D3 receptors prevail at lower doses (increased dopamine 
  transmission), at higher doses, amisulpride acts preferentially 
on postsynaptic D2/D3 receptors, reducing dopaminergic 
transmission.32
Randomized controlled studies on the treatment of TS 
with amisulpride are lacking. As far as we know, only three 
case reports have been published on the treatment of TS 
with amisulpride, of which one was published in French.49 
The second case report describes the effective treatment of 
TS with moderate doses of amisulpride (maximum 400 mg/
day). One adverse event concerning amenorrhea was reported 
by a patient.50 Another case report on a patient with atypical 
TS as a tardive dyskinesia, indicated a change of medication 
from olanzapine to amisulpride.51
Conclusion: Because of the lack of randomized controlled 
studies, amisulpride cannot be recommended as first-line 
medication for the treatment of TS. Amisulpride could be 
seen as a second-choice medication given several expert 
opinions.32 Further studies are necessary to obtain valid 
results on its effectiveness.
Clozapine
Clozapine was first introduced in Europe in 1971, and was 
approved by the FDA to treat refractory schizophrenia in 
1989.52 It acts as a 5-HT2A, 5-HT2C, and 5-HT3 antagonist 
and, to a lesser extent, as a D1 antagonist.9 It has only a weak 
D2 blocking effect and may therefore be less effective in 
treating tics than other antipsychotics. A few older studies 
reported successful reductions in tics during monotherapy 
(as shown by Jaffe et al53 in the context of tardive TS) or in 
combination with propanolol or tetrabenazine.54 However, 
clozapine has not been found helpful in the treatment of 
TS as stated by several case reports which also documented 
serious adverse events (eg, agranulocytosis) associated 
with this agent.55 Furthermore, the occurrence of stuttering, 
facial tics, myoclonic seizures,56 and even the exacerba-
tion of tics seems to be related to the administration of 
clozapine.57
Conclusion: Due to the lack of efficacy and its potentially 
severe side effects, we would not recommend clozapine for 
the treatment of TS symptoms.
Risperidone
Risperidone acts as a 5-HT2 receptor antagonist at low doses 
and as a D2 antagonist at higher doses.58 It, too, has moderate-
to-high affinity for α1-adrenergic, D3, D4, and H1-histamine 
receptors.11 Risperidone can prolong the QTc interval, and 
weight gain can be an emerging problem.58–61 Our search 
period includes many well-executed studies. Bruggeman 
and colleagues suggest that risperidone may improve tic 
symptoms in 30%–62% of patients25 although some studies 
have reported even greater success rates.62 The efficacy Neuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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of risperidone has been confirmed by two   randomized, 
double-blind, placebo-controlled trials.63,64 Furthermore, 
risperidone was found to be equally effective or possibly 
slightly more effective than pimozide in two randomized, 
double-blind, crossover studies.25,26 Compared with 
haloperidol, risperidone showed slightly better tic reduction 
(28% vs 21%) but the difference in efficacy between the two 
drugs was not significant.65 In a randomized, double-blind 
study, risperidone and clonidine appeared equally effective 
in the treatment of tics.66 Additionally, many older studies 
reported a positive response67–70 with a similar efficacy to 
haloperidol. A high discontinuation rate seems to be one 
major drawback in the use of risperidone. It is suggested 
that only 20%–30% of patients can tolerate the use of this 
medication in the long term due to the associated side 
effects.71 Risperidone was also effective in treating obsessive–
compulsive symptoms.25,66,72 Moreover, risperidone could also 
be useful in ameliorating aggressive behaviour.73,74
Conclusion: The effectiveness of risperidone has been proven 
in several studies with high methodical demands. It seems 
that this drug is as effective as haloperidol in treating tics 
and may be also effective in treating comorbidities like 
obsessive–compulsive and aggressive symptoms. Therefore, 
we recommend risperidone as standard therapy. An unfavor-
able aspect of risperidone is the high discontinuation rate 
which may be due to common adverse events like fatigue, 
somnolence, and weight gain.22
Olanzapine
Olanzapine is an atypical neuroleptic with moderate-to-high 
affinity for D2, D4, 5-HT2A, 5-HT2C, and α-1 adrenergic recep-
tors, as well as D1 receptors.75 Compared with other antipsy-
chotics, olanzapine has greater activity at serotonin 5-HT2 
receptors than at D2 receptors,76 which may explain the few 
extrapyramidal effects. A lower incidence of  hyperprolactine-
mia than with typical antipsychotic agents or risperidone 
could be explained by the presumption that this drug does not 
appear to block dopamine within the tuberoinfundibular tract. 
The most widely reported adverse reactions were drowsiness/
sedation and increased appetite, frequently followed by weight 
gain.77,78 Because of metabolic adverse reactions, caution 
is recommended in case of hyperglycemia and diabetes. 
Recently published open-label trials have shown improvement 
in tic scores.76,77 In 60 children treated for 4 weeks with either 
olanzapine or haloperidol, efficacy in terms of tic severity 
reduction and global clinical impression was found to be 74% 
for both groups, though olanzapine was associated with fewer 
side effects.81 Other studies indicated that olanzapine leads to 
significant reductions in tic severity and even in aggression. 
The only identified drawback was weight gain.75 In an older, 
double-blind, crossover study, olanzapine seemed to be better 
at reducing tics in four patients with severe tics compared with 
low-dose pimozide.80 In addition, several older case reports81–84 
and open-label studies85,86 have suggested efficacy of olanzap-
ine in the   treatment of TS in adolescents and adults.
Conclusion: The major drawback of olanzapine is the valid 
concern about adverse metabolic effects and weight gain 
as known from the treatment of schizophrenia and bipolar 
disorder. Apart from this, the early use of olanzapine to treat 
TS can be recommended based on studies which have shown 
olanzapine to be as effective as haloperidol or pimozide. 
Additionally, this drug can reduce symptoms of ADHD and 
aggression.22
Quetiapine
Quetiapine antagonizes 5-HT1a, 5-HT2, D2, histamine H1, 
and α1 and α2 adrenergic receptors.11 Up to now, its efficacy 
for tic suppression is based solely on case reports which 
include, for example, the effective treatment of two chil-
dren with TS.87 In an open-label trial with twelve children, 
quetiapine reduced tics significantly.88 In the beginning, the 
main adverse event was sedation. During the 8 weeks under 
investigation, patients did not experience extrapyramidal 
adverse reactions and no statistically significant weight gain. 
Quetiapine reduced tic severity scores by over 60% after week 
4 in a retrospective review of 12 patients of ages 8–18 years 
in which, contrary to the study mentioned before, the only 
noteworthy adverse reaction was increased weight.89
Conclusion: The few available studies which mainly concen-
trate on patients under 18 years suggest that quetiapine could 
be effective in the treatment of TS and is associated with a 
tolerable side-effect profile, although weight gain and fatigue 
are fairly common. Due to the lack of methodologically well-
executed studies, no further statement can be given.
Ziprasidone
Ziprasidone pharmacological actions work by D2 and 
5-HT antagonism and blocking other neurotransmitters 
such as norepinephrine, serotonin, and adrenaline. It 
also has a moderate affinity for H1 receptors. The near 
absence of weight gain makes it attractive for the treatment 
of TS in obese patients.90 Generally, ziprasidone has a 
higher risk for prolongation of the QT-interval than other 
compounds such as risperidone, olanzapine, or haloperidol.11 
The most frequently reported adverse event is a mild 
transient somnolence.91,92 An open-label study including Neuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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24 children and adolescents with tic disorders indicated 
that a single dose of ziprasidone was well tolerated without 
clinically significant effects on electrocardiogram.93 Efficacy 
was evaluated in an older, randomized, double-blind, placebo-
controlled study including 28 children and adolescents, where 
ziprasidone appeared to be significantly more effective than 
placebo in reducing tics and was well tolerated.91 A case 
report described the induction of tardive symptoms in a 
28-year-old patient suffering from vocal tics secondary to 
treatment with ziprasidone. Additionally, anxiety and tension 
seemed to be aggravated by an increase in the drug. However, 
vocal tics resolved approximately 4 days after cessation.94
Conclusion: Although the availability of recent data is too 
restricted to draw a final conclusion, ziprasidone could be 
used as an attempt if first-line medication was not   effective. 
Apart from QT-prolongation, this drug has a favorable side-
effect profile and initial promising results give hope for 
upcoming studies.
Aripiprazole
Aripiprazole is one of the newest antipsychotics with a unique 
mechanism of action since it works as a partial agonist on 
the D2 receptors.22 It also has a high affinity with the sero-
tonin receptor system, working as an antagonistic on 5-HT2A 
receptors,95,96 and a partial agonistic on 5-HT2C and 5-HT1a 
receptors.97 Despite the lack of randomized double-blind and 
placebo-controlled studies, since 2004 more than 200 cases 
in at least 25 mostly open studies have been published, 
reporting good efficacy of aripiprazole in the treatment of 
tics for both adults and children.95,98–120 For instance, one 
larger retrospective study describes tic reduction in 29 of 
the 37 patients, who all tolerated the drug and continued the 
treatment.95 In general, aripiprazole is well tolerated and side 
effects (insomnia, fatigue, drowsiness, nausea, tremor, and 
agitation121) are usually mild-to-moderate and most often 
transient. At equivalent doses, aripiprazole is characterized 
by a safer cardiovascular profile than pimozide.23 Weight gain 
during treatment with aripiprazole is controversial, however. 
While some studies report negligible weight gain,101,117 others 
have described weight increase in 22%95 and up to 50%112 of 
patients. Murphy and colleagues115 noticed a mean increase 
of 2.3 kg after a 6-week trial in an open-label, flexible-dose 
study with 16 children.
Conclusion: Despite the lack of studies with high 
  methodological standards, the treatment of TS with 
  aripiprazole seems possible to recommend as a second 
choice, due to its unique mechanism of action, its mostly 
harmless side-effect profile, and the good clinical experiences 
reported. At least two studies have judged its effectiveness 
to be superior to that of previous pharmacological treatment 
options, even in refractory cases.9,98
Discussion
The importance of neuroleptics in the treatment of tics and 
TS is illustrated by the fact that haloperidol and pimozide 
are the only drugs that are approved for therapy of these 
disorders by the FDA. This approval is based on older trials, 
however. As our research has shown, the trials representing 
the basis for the pharmacological treatment of TS with   typical 
antipsychotics are rather old and vary in their results and 
methodological designs. For example, assessments range 
from subjective   self-rating scales of varying complexity to 
standardized   counting of tics based on video recordings. 
Furthermore, many studies include both children and adults 
which often results in the suggestion that both groups should 
be treated in similar ways, apart from drug dosages. At the 
same time, many experts prescribe these older drugs rather 
reluctantly due to the nature of their adverse events, especially 
when treating the typical patient population which consists 
of children and younger people. In line with this, the few 
existing guidelines for the pharmacological   treatment of tics 
and TS9,122–124 and helpful papers with treatment advice and 
suggested strategies11,22 mainly recommend the use of atypi-
cal antipsychotics as first-line treatment rather than typical 
neuroleptics. The main reason for this preference for atypical 
antipsychotics seems to be their different side-effect profiles 
and their efficacy in the reduction of tic symptoms. But for 
the example of clozapine, in particular, as the present review 
shows, it would be wrong to assume this efficacy to be a 
group effect of antipsychotic agents in general. Among the 
atypical antipsychotics, risperidone is the best studied agent 
for the treatment of TS. This, in combination with its positive 
outcomes, makes this drug, in our and other experts’ opinion, 
first choice.9,22,124
Yet this review of the literature shows that there is   currently 
insufficient evidence-based data on the available second-
generation antipsychotics, apart from risperidone (Figure 1). 
Maybe the fact that TS in adulthood is a relatively rare   disorder 
could partially explain why the pharmaceutical industry 
seems to be making only a marginal effort to approve modern 
a  ntipsychotics for the treatment of TS. This is   regrettable 
especially given the promising results for aripiprazole and 
olanzapine in methodologically “low level” studies. The efficacy 
of other promising compounds has not yet been studied either. 
Asenapine125,126 and sertindole127 are, based on their mechanism 
of action, possibly capable of reducing tics. But up to now Neuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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there is no evidence-based information available on these 
agents in the treatment of TS. Further research is needed.
The usual fluctuation in both severity and nature of symp-
toms over time, known as “waxing and waning”, complicates 
the objective measurement of symptom severity in studies. 
In addition, it is necessary to know that long-term treatment 
with neuroleptic, antiepileptic medication, or stimulants 
can cause tardive TS, which is characterized by the occur-
rence of multiple motor and vocal tics as well.128 As well as 
neuroleptics, some experts suggest that alpha-agonists such 
as clonidine or even guanfacine as first-line therapy have 
fewer adverse events.129 The existing data for these agents are 
relatively limited, however, and mainly ascribable to smaller, 
placebo-controlled studies.130,131 Thus we lack empirical data 
in support of alpha-agonists, compared with antipsychotics, 
and on atypical antipsychotics in general. Large, double-blind, 
placebo-controlled studies and well executed head-to-head 
comparisons are urgently required, especially those referring 
to modern, evidence-based criteria. Multicenter studies and 
independent, well-trained video-raters could be useful to con-
sider larger numbers of patients, and to collect more reliable 
information on the reduction of Tourette symptoms.
Limitations
The fact that we have only searched PubMed could cause a 
certain bias in the collection of considered publications, but 
we assume that all relevant papers are available in PubMed 
because all highly renowned journals are listed in this data-
base. For many agents presented, the data found were too poor 
to allow any specific conclusions about a drug. We assume this 
problem to be caused by the generally limited evidence-based 
data dealing with TS and tics rather than our search criteria.
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